Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mirdametinib - SpringWorks Therapeutics

Next Previous
X
Search
Drug Profile

Mirdametinib - SpringWorks Therapeutics

Alternative Names: PD-0325901; PD-325901

Latest Information Update: 19 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AstraZeneca; BeiGene; BIOENSIS; Memorial Sloan-Kettering Cancer Center; Pfizer; SpringWorks Therapeutics; St. Jude Childrens Research Hospital; University of Oxford
  • Class Aniline compounds; Anti-inflammatories; Antineoplastics; Benzamides; Immunotherapies; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neurofibromatosis 1
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Plexiform neurofibroma
  • Phase I/II Glioma; Solid tumours
  • Preclinical Rhabdoid tumour; Teratoma
  • No development reported Cervical cancer; Chronic obstructive pulmonary disease
  • Discontinued Breast cancer; Cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 12 Nov 2024 Efficacy data from a phase I/II trial in Glioma released bySpringWorks Therapeutics
  • 11 Nov 2024 Efficacy data from a phase II b ReNeu trial in neurofibromatosis type 1released by SpringWorks Therapeutics
  • 02 Sep 2024 FDA assigns PDUFA action date of (28/02/2025) for Mirdametinib for Neurofibromatosis 1

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top